Shares of Novavax Inc.
tumbled 12.2% in trading on Tuesday after a Reuters report said there are delays shipping the company’s COVID-19 vaccines to Europe and the Philippines in the first quarter of the year. Novavax’s vaccine has been authorized in several countries, including the U.K. and New Zealand. It is currently under review by the Food and Drug Administration for emergency authorization. The company did not immediately return a request for comment. Novavax’s stock is down 73.8% over the past year, while the broader S&P 500
is up 15.3%.